Schizophrenia and bipolar disorder affect millions of Americans, yet current diagnostic methods rely heavily on subjective assessments, long-term observation, and patient self-reporting. Research suggests misdiagnosis rates may exceed 50%1, and current methods often require 1–3+ years to reach a conclusion.
The designation highlights the potential of Laguna’s approach to address a longstanding challenge in psychiatry, where diagnosis often relies on subjective assessment, extended observation, and patient-reported symptoms—frequently resulting in delayed or uncertain diagnoses.
Laguna’s test uses mRNA biomarker signatures derived from a simple venous blood sample to generate an objective probability score that may help distinguish between schizophrenia and bipolar I disorder. The test is intended for use in conjunction with clinical assessment and other patient information and is not a standalone diagnostic.